Navigation Links
QRxPharma Limited Announces A$14 Million Placement Together With a Share Purchase Plan
Date:10/1/2010

details of the SPP will be sent to shareholders in due course.  

QRxPharma CEO and Managing Director, Dr John Holaday commented, "We are encouraged by the strong level of support we received for this offering as we progress towards the commercialization of our Dual Opioid portfolio of products. QRxPharma is pleased to be one of the few Australian companies with a drug in the final stages of clinical development."

"MoxDuo has the potential to revolutionize the management of pain from the hospital to the home. We have administered MoxDuo IR to well over 500 patients with moderate to severe pain following bunionectomy or total knee replacement surgery, and data indicate excellent pain relief with a 50-75% reduction in moderate to severe side effects. Results from our Phase 3 studies set the stage for NDA filing with the FDA, and once approved, we anticipate the launch of MoxDuo IR into the US$12 billion marketplace in the US and Europe in 2012," he added.  

Further details regarding the timetable for the Placement and Share Purchase Plan are included in the Annexure to this announcement.

Forward Looking Statements

This release contains forward-looking statements.  Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations.  Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement.  These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma.  Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties.  A number of important factors could
'/>"/>

SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014   Memorial Hermann Health System ... Center today announced a new partnership to provide a ... community breast care centers in the greater Houston ... Anderson will become the exclusive provider of professional breast radiology ... located in Memorial City, The Woodlands , ...
(Date:8/21/2014)... 21, 2014 Nektar Therapeutics (NASDAQ: ... announced positive results from its Phase 3 pivotal ... half-life recombinant factor VIII (rFVIII) treatment for hemophilia ... met its primary endpoint in reducing annualized bleed ... the on-demand arm. Top-line results from ...
(Date:8/21/2014)... The spinal column is one of the most delicate and ... from the brain through the column control many key functions ... here can be life altering, and leave the victim in ... body. Though back injury and disease can have an intensely ... available to make things better than ever before. Laser ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2
... 6, 2011 NeuroSigma, Inc., a Los Angeles-based ... a notice of award for an NIH Small ... the National Institute of Neurological Disorders and Stroke ... trigeminal nerve stimulation (eTNS™) therapy for the treatment ...
... NEW YORK, Sept. 6, 2011 ... research report is available in its ... Vaccines - Cell Culture Technology Gradually ... http://www.reportlinker.com/p0610894/Manufacturing-of-Vaccines---Cell-Culture-Technology-Gradually-Replacing-Egg-Based-Manufacturing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication Manufacturing ...
Cached Medicine Technology:NeuroSigma Receives Notice of Award from NIH for an STTR Grant for its Trigeminal Nerve Stimulation Therapy for Epilepsy 2Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 2Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 3Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 4Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 5Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 6Manufacturing of Vaccines - Cell Culture Technology Gradually Replacing Egg-Based Manufacturing 7
(Date:8/22/2014)... need surgery for facial pain caused by trigeminal neuralgia, ... reports a study in the September issue of ... Congress of Neurological Surgeons . The journal is published ... of Wolters Kluwer Health . , Percutaneous stereotaxic ... cost than other types of surgical treatments for trigeminal ...
(Date:8/22/2014)... Key West Health & Beauty’s ( ... much anticipated study results of the 12 best and ... an accompanying infographic on their website. It appears that ... major impact on the skin and contribute to many ... When asked how they determined the results, founder and ...
(Date:8/22/2014)... According to the new research ... Global Trends & Forecast to 2019" defines and ... forecast of the market value. The isocyanate material ... 2019, at a significant CAGR from 2014 to ... 44 figures spread through 286 pages and in-depth ...
(Date:8/22/2014)... 22, 2014 Braverman Eye Center is ... Lauderdale at the most affordable fee. They are on ... their advanced Lasik treatments. LASIK is a highly successful ... Eye Center has been delivering successful LASIK solutions to ... glasses-free and contact lenses-free life with the help of ...
(Date:8/22/2014)... A new study finds a wide range of ... related to key environmental exposuresin children with Crohn,s disease (CD), ... of the Crohn,s & Colitis Foundation of America ... & Wilkins , a part of Wolters Kluwer Health ... alterations of DNA in several regions of the genome in ...
Breaking Medicine News(10 mins):Health News:More common procedures for painful facial tics carry high costs, reports study in Neurosurgery 2Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 2Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 3Health News:Isocyanate Market An Industry Growing Steadily Projected to Grow $38,729 Million by 2019 - Report by MarketsandMarkets 4Health News:Braverman Eye Center Now Offers Lasik Treatment in Fort Lauderdale at the Most Affordable Fee 2Health News:Study shows epigenetic changes in children with Crohn's disease 2
... associated protein-1 (TRAP-1) may prevent cancer cell death. The ... as a Novel Molecular Target in Localized and Metastatic Prostate ... American Journal of Pathology . Prostate cancer is the ... cause of cancer deaths among men in the United States, ...
... are not as stringent as with new medications , TUESDAY, ... Administration may not be as stringent in evaluating devices as ... report in the Dec. 23/30 issue of the Journal ... often sails through based on studies that are not randomized ...
... stick to your workout routine, even in foul weather , ... chill on even the most enthusiastic exerciser,s plans. It,s hard ... sidestep icy patches. And who wants to go to the ... windshield first? , But sticking to your exercise program throughout ...
... have replaced the street as easy source of medications, experts ... death of pop star Michael Jackson in 2009 drew new ... States. , And with that attention has come acknowledgment ... five teenagers and adults -- about 50 million Americans -- ...
... the lab, expert says , TUESDAY, Dec. 29 (HealthDay ... cause some germs to develop resistance to antibiotics, new ... outside of the laboratory and they don,t suggest that ... "It is OK to use disinfectants. Just don,t misuse ...
... Texas, Dec. 29 Top marketing representatives ... Global Hotel Alliance brand members recently hosted a unique "Lasso ... The luxury hotel brands from across the world readily joined forces ... GHA associate who succumbed to lymphoma cancer in May. ...
Cached Medicine News:Health News:The cancer 'TRAP' 2Health News:Study Questions FDA Approvals of Cardiac Devices 2Health News:Study Questions FDA Approvals of Cardiac Devices 3Health News:Study Questions FDA Approvals of Cardiac Devices 4Health News: Winter Exercise Can Lift Your Spirits 2Health News:In U.S., Prescription Drug Abuse Is Growing 2Health News:In U.S., Prescription Drug Abuse Is Growing 3Health News:In U.S., Prescription Drug Abuse Is Growing 4Health News:Disinfectant Misuse Might Help Germs Resist Antibiotics 2Health News:Disinfectant Misuse Might Help Germs Resist Antibiotics 3Health News:Omni Hotels & Resorts and Global Hotel Alliance Partner for Charity 2Health News:Omni Hotels & Resorts and Global Hotel Alliance Partner for Charity 3